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Theenergetically demandingprocessof translation is
linked to multiple signaling events through mTOR-
mediated regulation of eukaryotic initiation factor
(eIF)4F complex assembly. Disrupting mTOR con-
straints on eIF4F activity can be oncogenic and alter
chemotherapy response, making eIF4F an attractive
antineoplastic target. Here, we combine a newly
developed inducible RNAi platform and pharmaco-
logical targeting of eIF4F activity to define a critical
role for endogenous eIF4F in Myc-dependent tumor
initiation. We find elevated Myc levels are associated
with deregulated eIF4F activity in the prelymphoma-
tous stage of theEm-Myc lymphomamodel. Inhibition
of eIF4F is synthetic lethal with elevated Myc in
premalignant pre-B/B cells resulting in reduced
numbers of cycling pre-B/B cells and delayed tumor
onset. At the organismal level, eIF4F suppression
affected a subset of normal regenerating cells, but
this was well tolerated and rapidly and completely
reversible. Therefore, eIF4F is a key Myc client that
represents a tumor-specific vulnerability.INTRODUCTION
The heterotrimeric eukaryotic initiation factor (eIF)4F complex
catalyzes the rate-limiting step of translation initiation by
stimulating ribosome recruitment to mRNA templates. This is
achieved through the coordinated action of the eIF4E subunit
(required for binding to mRNA 50 cap [5
0
m7GpppN3
0
] structures),
ATP hydrolysis (mediated by two eIF4A isoforms [eIF4AI andeIF4AII]), and interaction between the eIF4G subunit and the
43S preinitiation complex. Different mRNAs show varying
dependencies on eIF4F for ribosome recruitment—a feature
attributed to accessibility of the mRNA 50 cap (Dever, 2002).
Altered signaling flux through the PI3K/Akt/mTOR pathway in
human cancers is associated with changes in eIF4F levels
and modification of the cancer cell proteome due to selective
translational effects (Rajasekhar et al., 2003). When elevated,
eIF4E, the rate-limiting subunit of eIF4F (Duncan et al., 1987),
antagonizes Myc-induced apoptosis and cooperates with Myc
in tumorigenesis (Li et al., 2003; Ruggero et al., 2004; Wendel
et al., 2004). As well, Myc exerts profound effects on protein
synthesis through regulation of ribosome biogenesis (van
Riggelen et al., 2010) and transcriptional control of the three
eIF4F subunits (Jones et al., 1996; Lin et al., 2008). Increases
in eIF4F activity have been shown to selectively stimulate the
expression of malignancy-related mRNAs by augmenting
nucleo/cytoplasmic transport of Cyclin D1 (Rousseau et al.,
1996) and translation of Mcl-1 (Wendel et al., 2007) and Myc
(Lin et al., 2008). The recent description of a Myc/eIF4F tran-
scription/translation-coupled mitogenic loop (Lin et al., 2008)
prompted us to develop a trackable mouse model to assess
the in vivo contribution of eIF4F to Myc-dependent tumor
initiation.RESULTS
Transient Suppression of eIF4E Delays Myc-Dependent
Tumor Initiation
Mouse models provide valuable platforms for identifying and
characterizing lesions that promote tumorigenesis and for
testing the significance of effector pathways downstream of
known oncogenes and/or tumor suppressors for their con-
tribution to cancer development and/or maintenance (SchmittCell Reports 1, 325–333, April 19, 2012 ª2012 The Authors 325
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Figure 1. Transient Suppression of eIF4E Delays
Myc-Dependent Tumor Initiation
(A) Kaplan-Meier plot illustrating tumor-free survival of
recipient C57BL/6 mice transplanted with 20 Em-Myc
lymphoma cells or 2 3 106 bone marrow cells from 4-, 5-,
and 6-week-old Em-Myc mice.
(B) Forward light scatter from a flow cytometer of B220+
splenocytes from 6-week-old C57BL/6 and Em-Mycmice.
This assay was used as an independent validation to
confirm the prelymphomatous nature of Em-Myc cells
used in the transplantation experiments in (A).
(C) Western blot analysis of c-Myc transcriptional targets
(eIF4E, eIF4AI, eIF4GI) in C57BL/6 (WT) and Em-Myc
HSCs, B220+sIgM pre-B cells, and splenocytes from
mice of the indicated ages.
(D) Suppression of eIF4E expression in B220+ cells iso-
lated from 6-week-old mice of the indicated genotype
pretreated with vehicle or DOX for 2 weeks.
(E) Kaplan-Meier plot showing lymphoma-free survival
of 4E.389/rtTA/Em-Myc (n = 12), 4E.610/rtTA/Em-Myc
(n = 10), and FLuc.1309/rtTA/Em-Myc (n = 14) mice that
had been treated with vehicle (red) or with DOX (black) for
21 days starting at 4 weeks of age.
See also Figure S1.and Lowe, 2002). In the Em-Myc lymphoma model, Myc expres-
sion is driven by the lymphoid-specific IgH enhancer (Em) and
becomes elevated in the pre-B/B cell compartment (Adams
et al., 1985). Significant insight into Myc biology has been ob-
tained using this model—from the finding that tumor-derived
Myc mutants uncouple proliferation from apoptosis (Hemann
et al., 2005) to the identification/characterization of ornithine
decarboxylase, the rate-limiting enzyme for polyamine biosyn-
thesis, as a Myc effector (Nilsson et al., 2005).
Sensitive transplantation assays of ostensibly healthy Em-Myc
mice have shown that the majority (90%) of Em-Myc donors,
between 4 and 6 weeks of age, do not harbor malignant
lymphoma cells (Langdon et al., 1986) (Figure 1A). In this prelym-
phomatous stage there is a polyclonal expansion of morpholog-
ically distinct pre-B cells (Figure 1B) that is offset by an increased
apoptotic index (Jacobsen et al., 1994; Langdon et al., 1986).
Subsequent acquisition of genetic lesions that block the cell
death program triggers tumorigenesis (Strasser et al., 1990).
Indeed, we have previously shown that enforced expression of
eIF4E can drive aggressive cancers by attenuating apoptosis
in this setting (Wendel et al., 2004). The Em-Myc mouse is
thus a powerful model to study the contribution of Myc
network components to tumor initiation, leading us to ask if
perturbed eIF4F activity is a premalignant feature of Em-Myc
pre-B/B cells.326 Cell Reports 1, 325–333, April 19, 2012 ª2012 The AuthorsTo this end, we analyzed extracts from wild-
type (WT) and Em-Myc hematopoietic stem cells
(HSCs), 4 week B220+sIgM, and 5–6 week
splenic cells (Figure 1C). Myc expression is not
elevated in Em-Myc HSCs but is appreciably
increased in Em-Myc B220+sIgM B cells and
splenocytes isolated from 4- to 6-week-old
mice compared to WT controls (Figure 1C).
The expression of all three eIF4F subunits isalso increased in Em-Myc B220+sIgM B cells and splenocytes
from 4- to 6-week-old mice relative to WT controls (Figure 1C).
These results are consistent with previous studies indicating
that eIF4E, eIF4AI, and eIF4GI, but not eIF4AII, are transcriptional
targets of Myc (Jones et al., 1996; Lin et al., 2008) and demon-
strate that eIF4F upregulation is a signature of premalignant
Em-Myc preB/B lymphocytes.
To address whether elevated levels of eIF4F in Em-Myc
pre-B/B cells represent an epigenetic change essential for
tumor initiation, we took advantage of a powerful platform that
combines optimized GFP-coupled small hairpin RNA (shRNA)
technology with a Flp/FRT recombinase-mediated cassette
exchange (RMCE) strategy to generate mice that conditionally
express potent shRNAs targeting eIF4E (McJunkin et al., 2011;
Premsrirut et al., 2011). Two independent miR-based shRNAs
(shRNAmir) that target the eIF4E coding region, 4E.389 and
4E.610, and one that expresses a neutral control shRNAmir
targeting Firefly Luciferase, FLuc.1309 (Premsrirut et al., 2011),
were introduced into the FRT-hygro-pA ‘‘homing cassette’’ at
the ColA1 locus of KH2 ES cells (see Figure S1A). These cells
also harbor a reverse tet-transactivator (rtTA2) targeted to the
Rosa26 locus (referred to herein as rtTA) enabling potent,
doxycycline (DOX)-inducible suppression of eIF4E (Figure S1B).
Mice generated from these ES cells show inducible suppres-
sion of eIF4E in a wide spectrum of cells and tissues, including,
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Figure 2. Inducible Suppression of eIF4E Reduces the B220+ B Cell Compartment, Impairs Cell Division, and Augments Apoptosis in
Premalignant B Cells
(A) Flow cytometry analysis of B220+ B cells isolated from 6-week-old transgenic mice that had been treated with vehicle or DOX for 2 weeks. Error bars denote
SEM (n = 3). *p < 0.002, as determined by the Student’s t test.
(B) Representative photographs of spleens and average spleen mass of indicated 6-week-old triple-transgenic mice that had been treated with vehicle or DOX
for 2 weeks. Red dotted lines represent the range of spleen masses from four 6-week-old control C57BL/6 mice. Error bars denote SEM (n = 4). *p < 0.001,
**p < 0.01.
(C) Flow cytometry analysis of spleen cells isolated from 4E.389/rtTA/Em-Myc mice and stained for the indicated cell surface markers. Each marker positive
population was also >90% GFP+. Error bars are SEM (n = 3).
(D) Cell-cycle distribution of B220+ splenic B cells of the indicated genotype and DOX-treatment cohorts. Results are expressed as the average of three inde-
pendent experiments (n = 3). *p < 0.01; **p < 0.05 for percent (%) G1 and S phase cells.
(E) In situ TUNEL analysis on freshly isolated splenic cells from 5 week transgenic mice that had been treated with vehicle or DOX for 6 days. Error bars denote
SEM (n = 3). *p < 0.05.
See also Figure S2.liver, spleen, skin, intestine, components of the hematopoietic
system, and embryo-derived fibroblasts (Premsrirut et al., 2011)
(Figures S1C and S1D; see below).
We crossed shRNAmir/rtTA and Em-Myc mice to generate
triple-transgenic progeny in which eIF4E expression was sup-
pressed during the prelymphomatous stage between 4 and
7 weeks of age. Robust induction of GFP expression and potent
suppression of eIF4E was apparent in pre-B/B B220+ cells from
4E.389/rtTA/Em-Myc and 4E.610/rtTA/Em-Myc mice on DOX
(Figure 1D). DOX-treated 4E.389/rtTA/Em-Myc and 4E.610/
rtTA/Em-Myc mice showed a significant delay in lymphoma
onset compared to either untreated controls or to DOX-treated
FLuc.1309/rtTA/Em-Myc mice (Figure 1E; p < 0.001 for 4E.389/
rtTA/Em-Myc mice and p < 0.01 for 4E.610/rtTA/Em-Myc).
We attempted to assess the consequences of eIF4E suppres-
sion on tumor cell maintenance by administering DOX to
4-month-old lymphoma-bearing 4E.389/rtTA/Em-Myc mice, but
no stable response to disease was noted, and GFP induction
was detected in only a minority of tumor cells (8%–20%)(data not shown). This either reflects a collapse of the rtTA-induc-
ible system as noted in other settings (Podsypanina et al., 2008),
alterations in the DOX- or sheIF4E-responsiveness of the target
cell population, and/or weak or mosaic sheIF4E expression—
the latter having been documented in this shRNAmir/rtTA
transgenic system (McJunkin et al., 2011). Nevertheless, our
results indicate that endogenous eIF4E is required for conversion
of Em-Myc pre-B/B cells to malignant lymphomas.
Suppression of eIF4E Reduces the B220+ Em-Myc
Pre-B/B Cell Compartment by Impairing
Cell Division and Apoptosis
To elucidate themechanism(s) responsible for the delayed tumor
onset, we analyzed the consequences of eIF4E suppression on
theBcell population in the different transgenic settings (Figure 2).
We observed a reduction in splenic (Figure 2A) and bone
marrow-derived (Figure S2A) B220+ cells (1.8- to 2.5-fold) in
DOX-treated 4E.389/rtTA/Em-Myc and 4E.610/rtTA/Em-Myc
mice relative to vehicle-treated controls. As well, no significantCell Reports 1, 325–333, April 19, 2012 ª2012 The Authors 327
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Figure 3. Inducible Suppression of eIF4E Impairs eIF4F Levels, Selectively Blocks Protein Synthesis, and Affects Production of Cyclin D1,
Mcl-1, and Myc
(A) Relative abundance of the eIF4F complex in B220+ cells from mice of the indicated genotype.
(B) Protein synthesis rates in B220+ cells assessed by [35S]methionine incorporation and TCA precipitation. Error bars denote SEM (n = 3).
(C) Western blot analysis of eIF4E-responsive targets in B220+ cells isolated from 6-week-old mice. Cells were isolated from 4E.389/rtTA (lane 1), 4E.389/rtTA/
Em-Myc (lane 2), and four independent C57BL/6 (lanes 3–6) or Em-Myc (lanes 7–10) mice.
(D) Western blot analysis showing reductions in Mcl-1, Cyclin D1, and Myc levels upon suppression of eIF4E in B220+ cells in vivo.
(E) qRT-PCR quantitation of the indicated mRNA levels from B220+ splenocytes (n = 6; *p = 0.003).
(F) Western blot analysis indicating levels of eIF4E targets upon eIF4E suppression in B220+ cells.
See also Figure S3.change in the pre-B/B cell population was observed in DOX-
treated FLuc.1309/rtTA/Em-Myc mice, and a modest effect
(<1.4-fold) was observed in DOX-treated 4E.389/rtTA mice
(Figures 2A and S2A). A significant reduction in spleen mass
(>2-fold; *p < 0.001; **p < 0.01) in DOX-treated 4E.389/rtTA/
Em-Myc and 4E.610/rtTA/Em-Myc mice was noted compared
to vehicle-treated controls, DOX-treated FLuc.1309/rtTA/Em-
Myc mice, or 4E.389/rtTA mice (Figure 2B). The CD4+ (T cells),
CD11b+ (monocyte/macrophages, granulocytes), and Gr-1+
(granulocytes) cell populations were not depleted upon eIF4E
suppression and even increased in some cases (Figure 2C).
These results indicate that Em-Myc pre-B/B cells are exquisitely
sensitive to eIF4E attenuation.
The differential effects of eIF4E inhibition on WT versus Myc
overexpressing B cells appeared to be a consequence of
impaired cell-cycle progression and increased apoptosis. The
cell-cycle distribution of B220+ cells was similar among
all untreated triple-transgenic mouse strains but altered in
B220+ cells derived from DOX-treated 4E.389/rtTA/Em-Myc
and 4E.610/rtTA/Em-Myc mice, both of which showed an
accumulation in G1 phase and reductions in S/G2 phase328 Cell Reports 1, 325–333, April 19, 2012 ª2012 The Authorspopulations (Figure 2D). Moreover, the percentage of apoptotic
B220+ cells in 4E.389/rtTA/Em-Myc mice was increased upon
DOX treatment compared to cells from vehicle-treated controls,
DOX-treated FLuc.1309/rtTA/Em-Myc, or 4E.389/rtTAmice (Fig-
ure 2E). Similar results were obtained in other settings—notably
in murine 3T3 fibroblasts and human hTert-BJ cells, where
coexpression of Myc and sheIF4E was associated with a pro-
liferative disadvantage (Figures S2B and S2C) and increased
apoptosis (Figure S2D). Taken together, these results indicate
that eIF4E suppression and Myc overexpression share a
synthetic lethal relationship that affects cell-cycle progression
and survival.
Suppression of eIF4E Impairs eIF4F Complex Formation
and Activity
Alterations in eIF4E levels lead to selective effects on transla-
tional output mediated through the eIF4F complex (Dever,
2002). To determine if eIF4F levels are perturbed in DOX-treated
4E.389/rtTA/Em-Myc mice, B220+ cells were isolated, and the
eIF4F complex was purified by m7GDP affinity chromatography
(Figure 3A). Reductions in all three eIF4F subunits were noted in
DOX-treated 4E.389/rtTA/Em-MycB220+ cells compared to cells
from untreated 4E.389/rtTA/Em-Myc or DOX-treated control
FLuc.1309/rtTA/Em-Myc mice (Figure 3A). Metabolic labeling
revealed only a modest reduction of 20% in global protein
synthesis in B220+ cells from DOX-treated 4E.389/rtTA/Em-Myc
and 4E.610/rtTA/Em-Myc mice (Figure 3B), with no alteration in
the global profile of newly synthesized proteins (Figure S3A).
Such results are consistent with what has been previously docu-
mented upon antisense suppression of eIF4E expression (Graff
et al., 2007) and imply that the consequences on translation of
altering eIF4E levels are due to its impact on specific mRNAs.
The effects of eIF4E suppression on pre-B/B cell-cycle
progression and apoptosis (Figure 2) are consistent with
previous observations that Cyclin D1, Myc, andMcl-1 are partic-
ularly sensitive to eIF4E levels (Lin et al., 2008; Rosenwald et al.,
1993; Wendel et al., 2007). Indeed, premalignant Em-Myc
pre-B/B cells showed elevated levels of all three proteins
(Figure 3C). Suppressing eIF4E expression led to reductions
in the levels of all three eIF4E-responsive targets in splenic
(Figure 3D) or bone marrow (Figure S3B) derived B220+ cells iso-
lated from DOX-treated 4E.389/rtTA/Em-Myc and 4E.610/rtTA/
Em-Myc, but not from vehicle- or DOX-treated FLuc.1309/rtTA/
Em-Myc mice. Reductions in Myc, Mcl-1, and Cyclin D1 protein
levels observed upon eIF4E suppression are not a consequence
of decreased transcript levels (Figure 3E) and were fully revers-
ible upon removal of DOX (Figure S3C). In addition, eIF4E
suppression had no consequences on expression from the
eIF4E-insensitive b-actin, IRES-driven GFP (Balvay et al.,
2007), and p27Kip1 mRNAs (Miskimins et al., 2001) (Figures 3D
and S3D). Reductions in Mcl-1, Cyclin D1, and Myc upon
eIF4E suppression wereMyc context dependent in vivo because
they were not observed in DOX-treated 4E.389/rtTA cells (Fig-
ure 3F). These findings define eIF4E as a Myc client responsible
for augmenting prosurvival and proliferative capacity through
effectors, such as Mcl-1 and Cyclin D1.
Pharmacological Suppression of eIF4F Activity Blocks
Em-Myc-Driven Tumor Initiation
To confirm and extend these genetic observations using a
chemical biology approach, we took advantage of silvestrol,
a small molecular inhibitor of the helicase activity of eIF4A,
another essential component of the 4F complex (Bordeleau
et al., 2008). Treatment of prelymphomatous Em-Myc mice for
3 weeks with silvestrol significantly delayed tumor onset (Fig-
ure 4A; p < 0.01). As noted for shRNA-mediated inhibition of
eIF4E, silvestrol inhibited proliferation of Em-Myc pre-B/B cells,
but not Em-Myc CD4+ or CD11b+ cells (Figures 4B and 4C).
This was associated with a prolongation of G1 and shortening
of S/G2 cell-cycle phases (Figure 4D), increased apoptosis (Fig-
ure 4E), and reductions in Mcl-1 and Cyclin D1 protein levels
(Figure 4F). Whether the growth inhibitory effects of silvestrol
were Myc context dependent was investigated utilizing NIH/
3T3 cells ectopically expressing Myc/ER, a chimeric protein in
which a mutant estrogen receptor (ER) ligand binding domain
is fused to the carboxy-terminal domain of c-Myc. In this system,
Myc/ER is constitutively expressed but only becomes active
when 4-hydroxytamoxifen (4-OHT) is supplied (Littlewood
et al., 1995). Indeed, NIH/3T3 cells were found to be more sensi-tive to silvestrol upon induction of Myc/ER by 4-OHT (Figure 4G).
The convergence of genetic and pharmacological phenotypes
confirms that Myc-expressing cells are sensitive to eIF4F
inhibition.
Although the R26-rtTA allele is not ubiquitously expressed in
the adult, it is well expressed in the gut and hematopoietic
compartments, allowing us to assess toxicity in settings often
most prone to drug-induced toxicities (Beard et al., 2006; Pre-
msrirut et al., 2011). We noticed that when 4-week-old 4E.389/
rtTA/Em-Myc mice were treated with DOX for 2 weeks, a reduc-
tion in body weight was apparent within 10 days (Figure S4A).
Analysis of tissues with low proliferative indices that express
GFP and sh4E.389 (i.e., liver; Figure S1C) showed no discernable
histological changes (data not shown). In contrast a significant
increase in apoptotic bodies in crypt epithelium, loss of goblet
cells, and the presence of immature/undifferentiated crypts
was apparent in intestines of DOX-treated 4E.389/rtTA/Em-Myc
mice (Figures S4B and S4C)—a tissue that displays strong
GFP induction and efficient shRNA-mediated attenuation of
expression by R26-rtTA (Figures S1C and S4B) (McJunkin
et al., 2011; Premsrirut et al., 2011). These phenotypic changes
were completely reversed upon DOX withdrawal (Figure S4B).
No differences in Ki-67 staining in intestines from DOX- or
vehicle-treated 4E.389/rtTA/Em-Myc mice nor discernible histo-
logical changes in intestines from DOX- or vehicle-treated
FLuc.1309/rtTA/Em-Myc mice were noticed (data not shown).
Thus, although suppression of eIF4E has profound effects on
some proliferating somatic tissues such as the intestine, these
are well tolerated on the short term and are completely reversible
without any discernible long-term negative impact on the
animal’s well-being.
DISCUSSION
Myc amplifications are frequent somatic copy-number alter-
ations in human cancers (Beroukhim et al., 2010). The effective-
ness of suppressing Myc as an anticancer therapeutic approach
at the organismal level has been shown using dominant-negative
forms of Myc (Soucek et al., 2008). Here, using both genetic and
pharmacologic approaches, we demonstrate that the eIF4F
complex functions as an essential Myc client during the initial
phases of tumorigenesis. This relationship is likely in place for
supporting normal B cell development where Mcl-1 has been
shown essential for development of pro-B cells and later on,
for maintenance of mature B lymphocytes (Opferman et al.,
2003), in contrast to Bcl2, which appears largely dispensable
for early pro-B, pre-B, and immature cell development
(Kelly et al., 2007). The pre-B cell origin of sporadic Em-Myc
lymphomas (Adams et al., 1985) is consistent with eIF4F being
a Myc client—leading to upregulation of Mcl-1 expression.
We find that inhibition of eIF4F significantly delayed Myc-
induced lymphomagenesis without overt toxicity to normal
hematopoietic cells and other tissues. The transgenic model
that we established did not allow us to probe the Myc-eIF4F
relationship in tumor maintenance due to apparent collapse of
the rtTA-inducible system (see above); however, we expect
such a relationship to also be relevant in established tumors
because curtailing eIF4F helicase activity with small moleculeCell Reports 1, 325–333, April 19, 2012 ª2012 The Authors 329
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Figure 4. Blocking Em-Myc-Driven Tumor Initiation by Pharmacological Suppression of eIF4F Activity
(A) Kaplan-Meier plot showing lymphoma-free survival of 4-week-old Em-Myc mice treated with or without 0.2 mg/kg silvestrol (n = 7; p < 0.01) for 23 days.
(B) Percent B220+ cells isolated from 6-week-old C57BL/6 or Em-Mycmice that had been treated with vehicle or silvestrol for 2 weeks. Error bar represent SEM
(n = 3). *p < 0.01.
(C) Percent CD4+ and CD11b+ cells isolated from 6-week-old C57BL/6 or Em-Myc mice that had been treated with vehicle or silvestrol for 2 weeks. Error bar
represent SEM (n = 3). *p < 0.001.
(D) Cell-cycle distribution of B220+ splenic B cells of the indicated genotype and drug treatments. Results are expressed as the average of three independent
experiments.
(E) In situ TUNEL analysis on freshly isolated splenic cells from 5-week-old mice that had been treated with vehicle or silvestrol for 6 days (n = 3 mice). *p < 0.001.
(F) Western blot analysis of eIF4F targets in splenic B220+ cells isolated from untreated or silvestrol-treated Em-Myc or C57BL/6 mice.
(G) Sensitivity of NIH/3T3 cells to silvestrol. NIH/3T3 or Myc/ER NIH 3T3 cells were exposed to vehicle or 250 nM 4-OHT for 18 hr and then to silvestrol for
an additional 24 hr at the indicated concentrations. Cell viability was determined using the Sulforhodamine B (SRB) colorimetric assay and is set relative to
vehicle-treated cells. Values represent the average of three biological replicates, and error bars denote SEM.
(H) Relationship among Myc, eIF4F, and eIF4E effectors leading to increased cell-cycle progression and survival advantage during the premalignant phase of
lymphomagenesis. The plus (+) sign indicates that increased eIF4F levels also stimulate c-Myc mRNA translation (Lin et al., 2008).
See also Figure S4.inhibitors (silvestrol or hippuristanol) (Cencic et al., 2009; Lucas
et al., 2009; Tsumuraya et al., 2011) or suppression of eIF4E by
systemic delivery of eIF4E antisense oligonucleotides (Graff
et al., 2007) in xenograft models all show significant anticancer
activity while not displaying overt cytotoxicity to nontransformed
cells. As well, Myc lymphoma cells expressing shRNAs to eIF4E
have a selective growth disadvantage (Mills et al., 2008), overex-
pression of eIF4E antagonizes Myc-dependent apoptosis (Li
et al., 2003; Ruggero et al., 2004), and gene amplification along
the Myc-eIF4F axis can evade mTOR- and PI3K-targeted
therapy (Ilic et al., 2011; Wendel et al., 2004).
We have not observed a loss in body weight with the use of sil-
vestrol even when administered daily for 4 weeks (data not
shown), consistent with previous studies documenting that
long-term administration of this compound is well tolerated—330 Cell Reports 1, 325–333, April 19, 2012 ª2012 The Authorsaffecting neither spleen or liver weights, nor altering liver amino-
transferase activity, and showing little effect on cells of the
hematopoietic lineage (Cencic et al., 2009). This may pertain to
differences in the degree/extent of translation inhibition achieved
in vivo with single daily doses of silvestrol versus chronic
suppression of eIF4E by DOX. Because silvestrol has a short
serum half-life (6 hr) (Saradhi et al., 2011), treatment with this
compound would result in cycles consisting of a period of trans-
lation inhibition followed by recovery. This is in contrast to the
chronic suppression of eIF4E expected from continuous admin-
istration of DOX to sheIF4E-expressing mice. Alternatively,
differences in the downstream consequences on translation of
inhibiting eIF4A versus eIF4E in vivo may also be contributing
to the differences in toxicity. Hence, a key advantage of the
shRNA system used herein is to predict on-target toxicities.
From thework presented here, we anticipate that eIF4F targeting
drugs with increased potency may have increased intestinal
toxicity, but such toxicities would be manageable.
Although previous studies have indicated that silvestrol can
have anticancer effects (Bordeleau et al., 2008; Cencic et al.,
2009; Lucas et al., 2009), the remarkable similarity between
results produced through RNAi-mediated or chemical inhibition
strongly suggests that silvestrol acts to limit cancer progression
through targeting eIF4F. Of note, other recent efforts informed
by RNAi or chemical biology-based screens have identified
chromatin and SUMOylation modifiers required for Myc-driven
tumorigenesis (Kessler et al., 2012; Mertz et al., 2011; Zuber
et al., 2011). Consequently, whereas Myc has long been consid-
ered ‘‘undruggable,’’ there are now several therapeutically viable
options for selectively targeting Myc oncogenic functions in
different contexts. Indeed, combination strategies using these
approaches might achieve greater potency and potentially
bypass resistance.
Regardless of these therapeutic possibilities, our studies
demonstrate that Myc can exert a role in tumor maintenance
via selective effects on the translation of specific mRNAs. The
eIF4F complex preferentially stimulates the translation of a
subset of mRNAs that harbors highly structured 50 untranslated
regions and that encodes regulators of cell growth, proliferation,
and apoptosis (Koromilas et al., 1992; Larsson et al., 2007;
Mamane et al., 2007). Large-scale changes to the cellular
transcriptome, as executed upon Myc elevation, are expected
to disproportionately alter the competitive ability of individual
cellular mRNAs for limiting eIF4F levels, leading to distinctive
translational changes (Dever, 2002). Our data indicate that
Myc exploits eIF4F’s mRNA discriminatory ability to selectively
upregulate such effectors (Figure 4H). In this manner Myc coor-
dinates changes in protein synthesis with its well-established
nuclear activities, a feature that may be important for normal
Myc function but that also creates an unnatural dependency
under conditions of aberrant and/or sustained Myc levels.
EXPERIMENTAL PROCEDURES
Reagents, Cell Culture, and Mice
shRNAs targeting eIF4E were designed and tested as previously described
(Paddison et al., 2004). Two of these, sh4E.389 (50-TTAAATTACTAGACA
ACTGGA-30) and sh4E.610 (50-TTTAGCTCTAACATTAACAAC-30), as well as
shFLuc.1309 (a neutral shRNA targeting Firefly luciferase; Premsrirut et al.,
2011) were targeted to the murine Col1A1 locus using a Flp/FRT RMCE
strategy in pre-engineered ES cells (Hochedlinger et al., 2005). All ES cells
were selected and maintained on irradiated (40 Gy) MEFs derived from the
DR4 mouse strain. ES cells were cultured in knockout Dulbecco’s modified
Eagle’s medium (Cellgro Mediatech) supplemented with 10% fetal bovine
serum (FBS), L-glutamine, penicillin-streptomycin, nonessential amino acid,
LIF (leukemia inhibitory factor), and 55 mM b-mercaptoethanol. Electropora-
tions with KH2 ES cells were performed with 50 mg pColTGM (aka CTGM)
and 25 mg pCAGGS-FLPe at 400V and 125 mF as previously described
(Premsrirut et al., 2011). ColAI-targeted clones were selected in hygromycin,
tested for GFP inducibility, and transgenic mice derived using tetraploid
embryo complementation.
Em-Mycmice were crossed to 4E.389/rtTA, 4E.610/rtTA, or FLuc.1309/rtTA
mice to generate triple-transgenic mice. Genotypes were obtained at the
expected Mendelian inheritance ratios. The Em-Myc transgene was detected
by genomic PCR amplification of a 600 bp product using the primers 50-GG
ACAGTGCTTAGATCCAAGGTGA-30 and 50-CCTCTGTCTCTCGCTGGAATTACT-30. Genotyping for R26-rtTA was performed using the primers 50-AA
AGTCGCTCTGAGTTGTTAT-30, 50-GCGAAGAGTTTGTCCTCAACC-30, and
50-GGAGCGGGAGAAATGGATATG-30. Genotyping for R26-rtTA yields two
PCR products of 500 bp (WT ROSA26 allele) and 300 bp (R26-rtTA allele).
Genotyping for 4E.389 by PCR used the primers 50-AATTACTAGACAACTG
GATTGCCT-30 and 50-GAAGAACAATCAAGGGTCC-30 (200 bp product),
whereas genotyping for 4E.610 by PCR used the primers 50-GCCACAGA
TGTATTTAGCTCTAAC-30 and 50-GAAGAACAATCAAGGGTCC-30 (200 bp
product). Genotyping for FLuc.1309 used the primers 50-CACCCTGAAAA
CTTTGCCCC-30 and 50-AAGCCACAGATGTATTAATCAGAGA-30 (300 bp
product).
All mice strains were maintained on a C57BL/6 background. Activation of
shRNAmir production in mice was performed in 4-week-old transgenic mice
by supplying DOX (1 mg/ml) in the drinking water (plus 5% sucrose) for the
indicated periods of time. DOX-supplemented water was changed every
4 days. To assess the impact of silvestrol on lymphoma onset, 4-week-old
Em-Myc mice were treated with vehicle (5.2% PEG 400/5.2% Tween 80) or
0.2 mg/kg silvestrol (daily intraperitoneal injections) for 23 consecutive days.
All mice were monitored twice a week for signs of morbidity and lymphoma
development, the latter scored by peripheral lymph node palpation. Tumor-
free survival is defined as the time from birth to the time of appearance of
a palpable lymphoma. Data were analyzed in the Kaplan-Meier format using
the log rank (Mantel-Cox) test for statistical significance. All animal studies
were approved by the McGill University Faculty of Medicine Animal Care
Committee.
Flow Cytometry
Fresh-cell suspensions were isolated in PBS plus 2% FBS. Erythrocytes were
removed by lysis in ACK buffer (150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM
EDTA). Remaining cells were collected by centrifugation and resuspended in
1 ml PBS plus 2% FBS. Blocking was performed by incubating samples
with purified anti-CD16/CD32 antibody (clone: 2.4G2; BD Biosciences) for
5 min on ice before labeling cells with fluorochrome-conjugated substrate-
specific antibodies. The forward and side light-scatter gate excluded small
apoptotic cells and granular cells, whereas large cells were included.
Antibodies used to identify monocytes and granulocytes were Ly-6G (Gr-1)
PECy7 (clone 1A8; BD Biosciences) and CD11b PE (clone M1/70; BD
Biosciences). Antibodies used to identify T and B lymphocytes were CD4 PE
(clone RM4-5; BD Biosciences) and CD45R/B220 PE (clone RA3-6B2; BD
Biosciences). Incubations were performed in the dark on ice for 20 min before
data acquisition, and analyses were conducted on a FACSAria II (BD Biosci-
ences). Erythrocytes, dead cells, and debris were excluded with gating based
on forward/side-scatter characteristics. The percent B and T lymphocytes,
monocytes, and granulocytes for each sample was expressed as a percentage
of total gated cells analyzed.
To measure apoptosis in vivo, TUNEL assays were performed on freshly
isolated splenic cells from indicated transgenic mice treated with vehicle or
DOX for 6 days following the manufacturer’s instructions (In Situ Cell Death
Detection Kit, TMR red; Roche).
For cell-cycle analysis, freshly isolated splenic B220+ cells from vehicle or
DOX-treated transgenic mice were incubated with 1 ml DNA-staining buffer
(0.3% Triton X-100, 50 mg/ml propidium iodine, 20 mg/ml RNase A, and
4 mM sodium citrate). Cell-cycle distribution was analyzed by flow cytometry
using a Guava EasyCyte (Millipore).
For silvestrol-treated C57BL/6 and Em-Myc mice, freshly isolated splenic
B220+ cells (106 cells/ml) were washed, fixed in 75% ethanol solution for
1 hr at 4C, and stained with propidium iodide (Sigma-Aldrich) (50 mg/ml
propidium iodide, 3.8 mM sodium citrate, and 500 mg/ml RNase A) for 3 hr at
4C. Cells were then analyzed for DNA content using a FACScan (BD
Biosciences).
Expression Analysis
For western blotting, cells were lysed in RIPA lysis buffer (50 mM Tris-HCl
[pH 7.5], 150 mM NaCl, 1 mM DTT, 0.1% SDS, 1% NP-40, 0.5% sodium
deoxycholate, 0.1 mM phenylmethylsulfonyl fluoride [PMSF], 1 mg/ml each
of leupeptin, pepstatin, and aprotinin). Protein concentrations were deter-
mined using the Bio-Rad Protein assay. Total protein lysates (30 mg) wereCell Reports 1, 325–333, April 19, 2012 ª2012 The Authors 331
resolved by SDS-PAGE, transferred to PVDF membranes (Millipore), probed
with the indicated antibodies, and visualized using enhanced chemilumines-
cence (ECL) detection (Amersham). Primary antibodies were as follows:
anti-cyclin D1 was from Cell Signaling Technology (#2926; Beverly, MA,
USA), and anti-Mcl-1 was purchased from AbD Serotec (#AHP1249; Oxford).
Anti-GFP (#sc-9996), anti-eIF4E (#sc-9976), anti-p27 (#sc-528), and anti-c-
Myc (#sc-764) antibodies were obtained from Santa Cruz Biotechnology.
Anti-b-actin (#A5316) and anti-tubulin (#T5268) antibodies were purchased
from Sigma-Aldrich.
For metabolic studies, 2 3 105 B220+ cells were isolated from vehicle or
DOX-treated triple-transgenic mice and seeded in 24-well plates. Cells from
DOX-treated mice were maintained in 1 mg/ml DOX. Cells were cultured for
45 min in methionine-free medium, followed by 60 min in [35S]methionine-
containing medium (150–220 mCi/ml) supplemented with 10% dialyzed FCS,
washed, and lysed in RIPA buffer. Proteins were TCA precipitated onto 3MM
Whatman paper, and the amount of radioactivity was quantitated by scintilla-
tion counting. Values were normalized to total protein levels as determined
by the Bradford assay.
For m7GTP Sepharose pull-down assays, freshly isolated cells were har-
vested in 300 ml of Lysis Buffer (20 mM HEPES7.5, 100 mM KCl, 1.0 mM
EDTA, 1 mM DTT, 1 mM PMSF, and 0.2% Tween 20, 10 mM NaF and
20 mM b-glycerophosphate), and then subjected to three cycles of freeze-
thaw. The lysate was then incubated with 50 ml of 50% slurry of m7GTP-
Sepharose 4B (GE Healthcare, UK) for 2 hr at 4C. The resin was washed
three times with 1 ml of Lysis Buffer and one time with buffer A containing
200 mM GDP. Finally, proteins bound to the resin were eluted with 80 ml of
m7GDP (1 mM) for 10 min on ice. Aliquots of the eluted fractions (25 ml) were
resolved by SDS-PAGE (10% polyacrylamide) and analyzed by western
blotting.
Immunohistochemistry and TUNEL Staining
Tissues were harvested, fixed in 10% formalin, and embedded in paraffin.
Sections (5 mm) were then dewaxed and rehydrated through a graded series
of alcohol washes to water. They were placed in 10 mM citric acid buffer
(pH 6.0) and subjected to antigen retrieval by boiling for 15 min. Immunohisto-
chemistry was performed using HRP/DAB Detection Kit (ab64261; Abcam)
according to the manufacturer’s instruction. Briefly, after incubation with
blocking buffer for 1 hr and 3% hydrogen peroxide for 10 min, rabbit anti-
eIF4E (catalog #9742; Cell Signaling) or rabbit anti-GFP (catalog #2555; Cell
Signaling) was applied overnight at 4C. Sections were washed with TBS-T
(1 M Tris-HCl [pH 7.5], 1.5 M NaCl, and 1% Tween 20) and incubated with bio-
tinylated goat anti-rabbit IgG for 30 min at room temperature. After washing
with TBS-T, streptavidin peroxidase was added for 30 min at room tempera-
ture. The signals were developed using DAB chromogen as substrate at
room temperature for 5 min. Sections were counterstained with hematoxylin,
dehydrated, and mounted with Permount. Apoptosis was detected with the
use of the ‘‘In situ Cell Death Detection Kit, POD’’ according to the manufac-
turer’s recommendations (Roche). Tissue sections were analyzed using an
Aperio ScanScope XT (Aperio Technologies, Vista, CA, USA).
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